MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer

MicroRNAs (miRNAs/miRs) are small, non-coding RNAs that reported to serve numerous important regulatory functions; however, the role of miRNAs in regulating breast cancer cell biology remains poorly understood. Accumulating evidence has demonstrated orchestrate multiple cellular functions and crucial roles differentiation development, either by acting as tumor suppressors or oncogenes. In particular, miR-155-5p expression levels have been found be upregulated a prognostic marker types solid cancer, including human cancer. More than half patients with benefit from treatment adjuvant paclitaxel chemotherapy following early postoperative period. Despite initial response intensive combination chemotherapy, majority most will eventually acquire resistance drug succumb their disease. Therefore, further investigations into association between mechanism required. The results present study revealed strong positive resistance, were resistant cells. MiR-155-5p was validated regulate using gain- loss-of-function experiments. TP53INP1 identified direct target gene combining prediction algorithm based on free energy minimization reverse transcription-quantitative PCR (qRT-PCR) analysis. Also, suggested key regulator cells, it increased viability motility, promoted paclitaxel-induced apoptosis. transfection inhibitors re-sensitized paclitaxel-resistant while overexpression led an increase paclitaxel. Furthermore, gene, TP53INP1, contributed re-sensitivity drug-resistant cells subsequent knockdown conferred sensitivity These may enhance understanding molecular mechanisms underlying progression novel therapeutic approaches combat therapy, well proliferation evasion apoptosis